左心室辅助装置患者的临终结局:INTERMACS注册研究分析
基于INTERMACS注册研究2008至2016年18,733例连续流左心室辅助装置(LVAD)患者,其中4,916例死亡,98%有死亡地点记录。76.9%的患者在医院死亡,随着植入后时间延长,院外死亡比例逐渐增加。死亡前数月生活质量保持临床稳定,死亡原因多样但卒中日益占主导。
要点
- 多数LVAD患者在医院死亡,植入后时间越长院外死亡比例越高。
- 高龄和目的地治疗指征增加院外死亡的可能性。
- 死亡前数月生活质量保持临床稳定,卒中为晚期主要死因。
核心结论
- 多数LVAD患者在医院死亡,死亡前数月生活质量保持稳定,死亡原因多样但卒中日益占主导。
研究设计与样本
- 基于INTERMACS注册研究,纳入2008至2016年植入连续流LVAD的18,733例患者,其中4,916例死亡,98%有死亡地点记录。
主要发现
- 76.9%的患者在医院死亡;植入后<1个月、1至12个月和>12个月的院外死亡比例分别为2.3%、16.8%和37.4%。
- 多变量分析显示,年龄增加(RR 1.06,95%CI 1.02-1.12,p=0.01)和目的地治疗指征(RR 1.15,95%CI 1.03-1.28,p=0.01)增加院外死亡可能性。
- 植入后3个月与死亡前6个月相比,生活质量保持临床稳定(EQ-5D VAS均值±SD:68.3±22.2降至66.7±21.7,p=0.11;KCCQ:61.0±22.2降至57.8±23.2,p=0.003)。
- 植入后<1个月最常见死因为多器官衰竭(20.4%),>1个月最常见死因为神经功能障碍(28.2%)。
临床怎么用
- 临床医生可依据死亡地点和时间分布,提前与患者及照护者沟通预期结局。
- 关注高龄和目的地治疗患者的院外死亡风险,提供针对性支持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trial and registry data have reported mortality rates and causes of death in patients with left ventricular assist devices (LVADs); however, a more granular description is needed of end of life, including location of death and quality of life (QOL), to better guide expectations and care. METHODS: To identify where patients with an LVAD died, characterize QOL before death, and cause of death over time, we evaluated patients in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) implanted with a continuous-flow LVAD. RESULTS: From 18,733 patients implanted with an LVAD during the period 2008 to 2016, 4,916 patients were known to have died, of whom 98% had a recorded location of death. Overall, 76.9% died in the hospital, with progressively more patients dying outside of the hospital further post-LVAD implant: <1 month, 2.3%; 1 to 12 months, and 16.8%; and >12 months, 37.4%. In a multivariable analysis, increased age (RR (risk ratio) 1.06, 95% confidence interval [CI] 1.02 to 1.12, p = 0.01) and destination therapy indication (RR 1.15, 95% CI 1.03 to 1.28, p = 0.01) increased the likelihood of dying outside the hospital. Comparing 3 months post-implant with 6 months before death in a subset of patients, QOL remained clinically stable (EQ-5D Visual Analog Scale [mean ± SD]: 68.3 ± 22.2 to 66.7 ± 21.7, p = 0.11; KCCQ: 61.0 ± 22.2 to 57.8 ± 23.2, p = 0.003). The most common cause of death <1 month post-implant was multiple-organ failure (20.4%) and at >1 month post-implant it was neurologic dysfunction (28.2%). CONCLUSIONS: Most patients with an LVAD died in the hospital. QOL remained stable months before death and causes of death were varied, but increasingly dominated by stroke. By understanding death with an LVAD in place, clinicians are in a better position to educate patients and caregivers about what to expect and provide to support tailored to patient and caregiver needs.
引用
- McIlvennan CK, Grady KL, Matlock DD, et al. End of life for patients with left ventricular assist devices: Insights from INTERMACS. J Heart Lung Transplant. 2018. PMID: 30642799. doi:10.1016/j.healun.2018.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。